
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 18, 2007**

Biogen Idec Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

0-19311

(Commission
file number)

33-0112644

(IRS Employer
Identification No.)

14 Cambridge Center, Cambridge, Massachusetts
(Address of principal executive offices)

02142
(Zip Code)

Registrant's telephone number, including area code **(617) 679-2000**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01 Regulation FD Disclosure.

On June 18, 2007, the registrant is presenting a Powerpoint slide showing a TYSABRI® (natalizumab) utilization and safety update at a symposium at the European Neurological Society meeting in Rhodes, Greece. A copy of the slide is furnished as Exhibit 99.1 and is incorporated herein by reference.

The Powerpoint slide is being furnished pursuant to Item 7.01 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Powerpoint slide showing a Tysabri utilization and safety update

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biogen Idec Inc.

By: /s/ Robert A. Licht

Robert A. Licht

Vice President and Assistant Secretary

Date: June 18, 2007

EXHIBIT INDEX

Exhibit
Number

Description

99.1 Powerpoint slide showing a Tysabri utilization and safety update

Natalizumab utilization and safety update

As of May 23, 2007...

- Approximately **12,000** patients were on TYSABRI therapy globally, including approximately 7,600 commercial patients in the US
 - Cumulatively, up to 21,000 patients had been exposed to TYSABRI in the clinical trial and post-marketing setting combined
- Approximately 1,700 physicians were prescribing TYSABRI in the US
- From July 18, 2006 to May 23, 2007, there have been no confirmed cases of PML or other serious opportunistic infections reported worldwide